vs
Side-by-side financial comparison of Agilent Technologies (A) and Alignment Healthcare, Inc. (ALHC). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.2B, roughly 1.5× Alignment Healthcare, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 0.9%, a 16.0% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs -74.7%). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (34.6% CAGR vs 6.9%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.
A vs ALHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.2B |
| Net Profit | $305.0M | $11.4M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | — |
| Net Margin | 17.0% | 0.9% |
| Revenue YoY | 7.0% | -74.7% |
| Net Profit YoY | -4.1% | — |
| EPS (diluted) | $1.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | $1.2B | ||
| Q4 25 | $1.9B | $1.0B | ||
| Q3 25 | $1.7B | $993.7M | ||
| Q2 25 | $1.7B | $1.0B | ||
| Q1 25 | $1.7B | $926.9M | ||
| Q4 24 | $1.7B | $701.2M | ||
| Q3 24 | $1.6B | $692.4M | ||
| Q2 24 | $1.6B | $681.3M |
| Q1 26 | $305.0M | $11.4M | ||
| Q4 25 | $434.0M | $-11.0M | ||
| Q3 25 | $336.0M | $3.7M | ||
| Q2 25 | $215.0M | $15.7M | ||
| Q1 25 | $318.0M | $-9.1M | ||
| Q4 24 | $351.0M | $-31.1M | ||
| Q3 24 | $282.0M | $-26.4M | ||
| Q2 24 | $308.0M | $-24.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -1.0% | ||
| Q3 25 | 20.7% | 0.8% | ||
| Q2 25 | 18.0% | 2.2% | ||
| Q1 25 | 22.4% | -0.6% | ||
| Q4 24 | 24.0% | -3.2% | ||
| Q3 24 | 21.1% | -2.8% | ||
| Q2 24 | 23.1% | -2.7% |
| Q1 26 | 17.0% | 0.9% | ||
| Q4 25 | 23.3% | -1.1% | ||
| Q3 25 | 19.3% | 0.4% | ||
| Q2 25 | 12.9% | 1.5% | ||
| Q1 25 | 18.9% | -1.0% | ||
| Q4 24 | 20.6% | -4.4% | ||
| Q3 24 | 17.9% | -3.8% | ||
| Q2 24 | 19.6% | -3.5% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.04 | ||
| Q3 25 | $1.18 | $0.02 | ||
| Q2 25 | $0.75 | $0.07 | ||
| Q1 25 | $1.11 | $-0.05 | ||
| Q4 24 | $1.23 | $-0.15 | ||
| Q3 24 | $0.97 | $-0.14 | ||
| Q2 24 | $1.05 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $705.6M |
| Total DebtLower is stronger | $3.0B | — |
| Stockholders' EquityBook value | $6.9B | $206.9M |
| Total Assets | $12.8B | $1.3B |
| Debt / EquityLower = less leverage | 0.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | $705.6M | ||
| Q4 25 | $1.8B | $604.2M | ||
| Q3 25 | $1.5B | $644.1M | ||
| Q2 25 | $1.5B | $503.8M | ||
| Q1 25 | $1.5B | $479.5M | ||
| Q4 24 | $1.3B | $470.6M | ||
| Q3 24 | $1.8B | $381.0M | ||
| Q2 24 | $1.7B | $363.7M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $323.2M | ||
| Q3 25 | $3.4B | $322.7M | ||
| Q2 25 | $3.3B | $322.3M | ||
| Q1 25 | $3.3B | $321.9M | ||
| Q4 24 | $3.3B | $321.4M | ||
| Q3 24 | $2.1B | $212.0M | ||
| Q2 24 | $2.1B | $211.7M |
| Q1 26 | $6.9B | $206.9M | ||
| Q4 25 | $6.7B | $179.3M | ||
| Q3 25 | $6.4B | $161.9M | ||
| Q2 25 | $6.1B | $141.0M | ||
| Q1 25 | $6.0B | $108.1M | ||
| Q4 24 | $5.9B | $99.9M | ||
| Q3 24 | $5.9B | $114.5M | ||
| Q2 24 | $6.2B | $123.7M |
| Q1 26 | $12.8B | $1.3B | ||
| Q4 25 | $12.7B | $1.1B | ||
| Q3 25 | $12.2B | $1.1B | ||
| Q2 25 | $12.2B | $1.0B | ||
| Q1 25 | $11.9B | $895.6M | ||
| Q4 24 | $11.8B | $782.1M | ||
| Q3 24 | $11.0B | $692.3M | ||
| Q2 24 | $10.9B | $716.3M |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.80× | ||
| Q3 25 | 0.53× | 1.99× | ||
| Q2 25 | 0.55× | 2.29× | ||
| Q1 25 | 0.56× | 2.98× | ||
| Q4 24 | 0.57× | 3.22× | ||
| Q3 24 | 0.36× | 1.85× | ||
| Q2 24 | 0.34× | 1.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $128.7M |
| Free Cash FlowOCF − Capex | $175.0M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 5.2% | — |
| Cash ConversionOCF / Net Profit | 0.88× | 11.27× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | $128.7M | ||
| Q4 25 | $545.0M | $-50.4M | ||
| Q3 25 | $362.0M | $144.6M | ||
| Q2 25 | $221.0M | $29.1M | ||
| Q1 25 | $431.0M | $16.6M | ||
| Q4 24 | $481.0M | $-8.7M | ||
| Q3 24 | $452.0M | $26.2M | ||
| Q2 24 | $333.0M | $23.5M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-55.4M | ||
| Q3 25 | $259.0M | $139.1M | ||
| Q2 25 | $107.0M | $21.1M | ||
| Q1 25 | $334.0M | $8.4M | ||
| Q4 24 | $388.0M | $-18.0M | ||
| Q3 24 | $360.0M | $16.9M | ||
| Q2 24 | $230.0M | $11.8M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -5.5% | ||
| Q3 25 | 14.9% | 14.0% | ||
| Q2 25 | 6.4% | 2.1% | ||
| Q1 25 | 19.9% | 0.9% | ||
| Q4 24 | 22.8% | -2.6% | ||
| Q3 24 | 22.8% | 2.4% | ||
| Q2 24 | 14.6% | 1.7% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 0.5% | ||
| Q3 25 | 5.9% | 0.6% | ||
| Q2 25 | 6.8% | 0.8% | ||
| Q1 25 | 5.8% | 0.9% | ||
| Q4 24 | 5.5% | 1.3% | ||
| Q3 24 | 5.8% | 1.3% | ||
| Q2 24 | 6.5% | 1.7% |
| Q1 26 | 0.88× | 11.27× | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | 38.77× | ||
| Q2 25 | 1.03× | 1.86× | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ALHC
Segment breakdown not available.
